Zoetis Inc. Annual Report, Year Ended Dec 31, 2014

Zoetis Inc. (ZTS) reported strong performance for the fiscal year ended December 31, 2014, marking its first full year as an independent public company following its separation from Pfizer in early 2013. The company demonstrated robust revenue growth of 5% year-over-year, reaching $4.79 billion, driven by solid operational performance across its global segments, particularly in the United States and emerging markets. This growth was fueled by both increased sales volume and price increases, supported by a diverse product portfolio targeting both livestock and companion animals. Key financial highlights include a 16% increase in Net Income Attributable to Zoetis, reaching $583 million. The company also reported a strong adjusted net income of $790 million, indicating effective management of operational costs and strategic investments in research and development. Zoetis's strategic focus on expanding its presence in emerging markets and developing new products, coupled with its established market leadership and customer relationships, positions it well for continued growth. The company's diversified revenue streams and focus on innovation in animal health medicine and vaccines present a stable and promising outlook for investors.